Cargando…

Fetuin-A Levels Are Increased in Patients With Type 2 Diabetes and Peripheral Arterial Disease

OBJECTIVE: Low levels of fetuin-A, a systemic calcification inhibitor, are linked to mortality in patients on dialysis. In contrast, elevated fetuin-A is associated with cardiovascular events in non-renal patients. We investigated fetuin-A in patients with type 2 diabetes and peripheral arterial dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorant, David Peter, Grujicic, Milan, Hoebaus, Clemens, Brix, Johanna-Maria, Hoellerl, Florian, Schernthaner, Guntram, Koppensteiner, Renate, Schernthaner, Gerit-Holger
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005446/ https://www.ncbi.nlm.nih.gov/pubmed/20929991 http://dx.doi.org/10.2337/dc10-0788

Ejemplares similares

Thrombospondin-4 increases with the severity of peripheral arterial disease and is associated with diabetes
por: Zierfuss, Bernhard, et al.
Publicado: (2019)

Angiogenin—A Proposed Biomarker for Cardiovascular Disease—Is Not Associated With Long-Term Survival in Patients With Peripheral Artery Disease
por: Höbaus, Clemens, et al.
Publicado: (2021)

Vascular peroxidase 1 is independently associated with worse kidney function in patients with peripheral artery disease
por: Costas, Lavinia, et al.
Publicado: (2020)

Peripheral arterial disease and type 2 diabetes: Older patients still exhibit a survival benefit from glucose control
por: Höbaus, Clemens, et al.
Publicado: (2020)

Cure of Type 2 Diabetes by Metabolic Surgery? A Critical Analysis of the Evidence in 2010
por: Schernthaner, Guntram, et al.
Publicado: (2011)

NT-proBNP as a surrogate for unknown heart failure and its predictive power for peripheral artery disease outcome and phenotype
por: Zierfuss, Bernhard, et al.
Publicado: (2023)

Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes
por: Höbaus, Clemens, et al.
Publicado: (2021)

Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery
por: Herz, Carsten T., et al.
Publicado: (2021)

Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2023)
por: Saely, Christoph H., et al.
Publicado: (2023)

Endothelial Progenitor Cells Are Related to Glycemic Control in Children With Type 1 Diabetes Over Time
por: Hörtenhuber, Thomas, et al.
Publicado: (2013)

YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease
por: Schernthaner, Gerit-Holger, et al.
Publicado: (2016)

Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
por: Schernthaner, Guntram, et al.
Publicado: (2013)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Renal Function but Not Asymmetric Dimethylarginine Is Independently Associated with Retinopathy in Type 2 Diabetes
por: Krzyzanowska, Katarzyna, et al.
Publicado: (2011)

Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
por: Schernthaner, Guntram, et al.
Publicado: (2018)

Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
por: Schernthaner, Guntram
Publicado: (2021)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
por: Schernthaner, Guntram
Publicado: (2021)

To the editor regarding article “Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study”
por: Mayer, Florian J., et al.
Publicado: (2018)

The importance of socio-economic determinants of health in the care of patients with peripheral artery disease: A narrative review from VAS
por: Kolossváry, Endre, et al.
Publicado: (2023)

Hypoglycemia and Cardiovascular Risks
por: Frier, Brian M., et al.
Publicado: (2011)

The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
por: Czupryniak, Leszek, et al.
Publicado: (2021)

Association of Lower Plasma Fetuin-A Levels With Peripheral Arterial Disease in Type 2 Diabetes
por: Eraso, Luis H., et al.
Publicado: (2010)

Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
por: Schernthaner, G., et al.
Publicado: (2016)

Involvement of APOE in Incidence of Revascularization in Patients Affected by Peripheral Arterial Disease: A Prospective Study from Southern Italy
por: Di Stolfo, Giuseppe, et al.
Publicado: (2023)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
por: Schernthaner, Guntram, et al.
Publicado: (2017)

Fetuin-A levels in hyperthyroidism
por: Pamuk, Barış Onder, et al.
Publicado: (2013)

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2017)

Fetuin, an inhibitor of lymphocyte transformation. The interaction of fetuin with phytomitogens and a possible role for fetuin in fetal development
Publicado: (1975)

Fetuin-A levels are increased in the adipose tissue of diabetic obese humans but not in circulation
por: Khadir, Abdelkrim, et al.
Publicado: (2018)

Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice
por: Unger, M. S., et al.
Publicado: (2018)

Increased UHMWPE Particle-Induced Osteolysis in Fetuin-A-Deficient Mice
por: Polan, Christina, et al.
Publicado: (2023)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Slope of change in HbA(1c) from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2018)

Urine and serum fetuin-A levels in patients with urolithiasis
por: Arora, Rajat, et al.
Publicado: (2017)

Association of mitral annular calcification with fetuin-A levels
por: Ağıllı, Mehmet, et al.
Publicado: (2015)

High Fetuin-A Levels in Children with Celiac Disease
por: Kurt, Nezahat, et al.
Publicado: (2022)

Fetuin-A, inflammation, and coronary artery calcification in hemodialysis patients
por: Turkmen, K., et al.
Publicado: (2011)

Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?
por: Nascimbeni, Fabio, et al.
Publicado: (2018)

Serum Fetuin-A levels are increased and associated with insulin resistance in women with polycystic ovary syndrome
por: Liu, Sha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hed0nhrpn16v9t49o0id8ra4nb